Skip to main content

Advertisement

SpringerLink
Log in

Probiotic Therapy (BIO-THREE) Mitigates Intestinal Microbial Imbalance and Intestinal Damage Caused by Oxaliplatin

  • Published:
Probiotics and Antimicrobial Proteins Aims and scope Submit manuscript

Abstract

Gastrointestinal mucositis associated with the use of chemotherapeutic drugs can seriously affect the quality of life of patients. In this study, a probiotic mixture, BIO-THREE, was used to alleviate intestinal damage caused by oxaliplatin in mice and human patients. Kunming mice were injected with 15 mg/kg of oxaliplatin twice, and BIO-THREE tablets were administered to mice for 12 days. Patients with gastric cancer undergoing oxaliplatin treatment took BIO-THREE tablets for 2 weeks. The changes in the composition of fecal microbiota both in patients and mice were analyzed using 16S rRNA high-throughput sequencing. In mice, oxaliplatin caused a drop in body weight and produced lesions in the liver and small intestines. Probiotic therapy successfully mitigated the damage caused by oxaliplatin to the intestinal tract, but it was not very effective for the liver damage and weight loss caused by oxaliplatin. The sequencing of the gut microflora indicated that oxaliplatin treatment increased the abundance of Bacteroidetes and decreased the abundance of Prevotella in mice. After taking probiotics, the feces of mice and human patients both had a higher abundance of Plovitella and a lower abundance of Bacteroides. The increase in Bacteroidetes and decrease in Prevotella in the gut community might be associated with oxaliplatin-induced intestinal damage. Probiotics appeared to be beneficial, decreasing intestinal damage by restoring the abundance of Bacteroidetes and Prevotella.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Availability of Data and Material

The datasets generated during the current study are available in the NCBI Sequence Read Archive (SRA) Database (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA659425/).

References

  1. Newsroom (2018) Cancer. World Health Organization. https://www.who.int/health-topics/cancer#tab=tab_1

  2. Ruiz-González R, Milán P, Bresolí-Obach R, Stockert JC, Villanueva A, Cañete M, Nonell S (2017) Photodynamic synergistic effect of pheophorbide a and doxorubicin in combined treatment against tumoral cells. Cancers (Basel) 9:18. https://doi.org/10.3390/cancers9020018

    Article  CAS  Google Scholar 

  3. Feather CE, Lees JG, Makker PGS, Goldstein D, Kwok JB, Moalem-Taylor G, Polly P (2018) Oxaliplatin induces muscle loss and muscle-specific molecular changes in mice. Muscle Nerve 57:650–658. https://doi.org/10.1002/mus.25966

    Article  CAS  PubMed  Google Scholar 

  4. Wang J, Feng W, Zhang S, Chen L, Tang F, Sheng Y, Ao H, Peng C (2019) Gut microbial modulation in the treatment of chemotherapy-induced diarrhea with Shenzhu Capsule. BMC Complement Altern Med 19:126. https://doi.org/10.1186/s12906-019-2548-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Stein A, Voigt W, Jordan K (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2:51–63. https://doi.org/10.1177/1758834009355164

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Abu-Sbeih H, Mallepally N, Goldstein R, Chen E, Tang T, Dike UK, Al-Asadi M, Westin S, Halperin D, Wang Y (2020) Gastrointestinal toxic effects in patients with cancer receiving platinum-based therapy. J Cancer 11:3144–3150. https://doi.org/10.7150/jca.37777

    Article  PubMed  PubMed Central  Google Scholar 

  7. Shen S, Lim G, You Z, Ding W, Huang P, Ran C, Doheny J, Caravan P, Tate S, Hu K, Kim H, McCabe M, Huang B, Xie Z, Kwon D, Chen L, Mao J (2017) Gut microbiota is critical for the induction of chemotherapy-induced pain. Nat Neurosci 20:1213–1216. https://doi.org/10.1038/nn.4606

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Touchefeu Y, Montassier E, Nieman K, Gastinne T, Potel G, Bruley des Varannes S, Le Vacon F, de La Cochetiere MF, (2014) Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - current evidence and potential clinical applications. Aliment Pharmacol Ther 40:409–421. https://doi.org/10.1111/apt.12878

    Article  CAS  PubMed  Google Scholar 

  9. Wilkins T, Sequoia J (2017) Probiotics for gastrointestinal conditions: a summary of the evidence. Am Fam Physician 96:170–178

    PubMed  Google Scholar 

  10. Seminario-Amez M, Lopez-Lopez J, Estrugo-Devesa A, Ayuso-Montero R, Jane-Salas E (2017) Probiotics and oral health: a systematic review. Med Oral Patol Oral Cir Bucal 22(3):e282–e288. https://doi.org/10.4317/medoral.21494

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wan C-F, Zheng L-L, Liu Y, Yu X (2016) Houttuynia cordata Thunb reverses oxaliplatin-induced neuropathic pain in rat by regulating Th17/Treg balance. Am J Transl Res 8:1609–1614

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Marmol I, Quero J, Rodriguez-Yoldi MJ, Cerrada E (2019) Gold as a possible alternative to platinum-based chemotherapy for colon cancer treatment. Cancers (Basel) 11(6):780. https://doi.org/10.3390/cancers11060780

    Article  CAS  Google Scholar 

  13. Chamaillard M, Stojanovska V, McQuade RM, Fraser S, Prakash M, Gondalia S, Stavely R, Palombo E, Apostolopoulos V, Sakkal S, Nurgali K (2018) Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon. PLoS ONE 13(6):e0198359. https://doi.org/10.1371/journal.pone.0198359

    Article  CAS  Google Scholar 

  14. Tsuda Y, Yoshimatsu Y, Aoki H, Nakamura K, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y (2007) Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol 42:1306–1311. https://doi.org/10.1080/00365520701396091

    Article  PubMed  Google Scholar 

  15. Yoshimatsu Y, Yamada A, Furukawa R, Sono K, Osamura A, Nakamura K, Aoki H, Tsuda Y, Hosoe N, Takada N, Suzuki Y (2015) Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World J Gastroenterol 21:5985–5994. https://doi.org/10.3748/wjg.v21.i19.5985

    Article  PubMed  PubMed Central  Google Scholar 

  16. Feng P, Ye Z, Han H, Ling Z, Zhou T, Zhao S, Virk AK, Kakade A, Abomohra AE, El-Dalatony MM, Salama ES, Liu P, Li X (2020) Tibet plateau probiotic mitigates chromate toxicity in mice by alleviating oxidative stress in gut microbiota. Commun Biol 3:242. https://doi.org/10.1038/s42003-020-0968-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Huber VC, Abdo Z, LeCureux J, LaVoy A, Eklund B, Ryan EP, Dean GA (2019) Impact of oral probiotic Lactobacillus acidophilus vaccine strains on the immune response and gut microbiome of mice. PLoS ONE 14(12):e0225842. https://doi.org/10.1371/journal.pone.0225842

    Article  CAS  Google Scholar 

  18. Liu M, Lu X, Khan A, Ling Z, Wang P, Tang Y, Liu P, Li X (2019) Reducing methylmercury accumulation in fish using Escherichia coli with surface-displayed methylmercury-binding peptides. J Hazard Mater 367:35–42. https://doi.org/10.1016/j.jhazmat.2018.12.058

    Article  CAS  PubMed  Google Scholar 

  19. Schultz KK, Strait EL, Erickson BZ, Levy N (2012) Optimization of an antibiotic sensitivity assay for Mycoplasma hyosynoviae and susceptibility profiles of field isolates from 1997 to 2011. Vet Microbiol 158:104–108. https://doi.org/10.1016/j.vetmic.2012.02.002

    Article  CAS  PubMed  Google Scholar 

  20. Yu X, Shi J, Khan A, Yun H, Zhang P, Zhang P, Kakade A, Tian Y, Pei Y, Jiang Y, Huang H, Wu K, Li X (2020) Immobilized-microbial bioaugmentation protects aerobic denitrification from heavy metal shock in an activated-sludge reactor. Bioresour Technol 307:123185. https://doi.org/10.1016/j.biortech.2020.123185

    Article  CAS  PubMed  Google Scholar 

  21. Yao Y, Lu Z, Zhu F, Min H, Bian C (2013) Successful bioaugmentation of an activated sludge reactor with Rhodococcus sp. YYL for efficient tetrahydrofuran degradation. J Hazard Mater 261:550–558. https://doi.org/10.1016/j.jhazmat.2013.08.007

    Article  CAS  PubMed  Google Scholar 

  22. Sookoian S, Pirola CJ (2015) Liver enzymes, metabolomics and genome-wide association studies: from systems biology to the personalized medicine. World J Gastroenterol 21:711–725. https://doi.org/10.3748/wjg.v21.i3.711

    Article  PubMed  PubMed Central  Google Scholar 

  23. Sorensen JC, Petersen AC, Timpani CA, Campelj DG, Cook J, Trewin AJ, Stojanovska V, Stewart M, Hayes A, Rybalka E (2017) BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice. Front Pharmacol 8:137. https://doi.org/10.3389/fphar.2017.00137

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Stringer AM, Al-Dasooqi N, Bowen JM, Tan TH, Radzuan M, Logan RM, Mayo B, Keefe DM, Gibson RJ (2013) Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer 21:1843–1852. https://doi.org/10.1007/s00520-013-1741-7

    Article  PubMed  Google Scholar 

  25. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6:1205–1218

    CAS  PubMed  Google Scholar 

  26. Mi H, Dong Y, Zhang B, Wang H, Peter CCK, Gao P, Fu H, Gao Y (2017) Bifidobacterium infantis ameliorates chemotherapy-induced intestinal mucositis via regulating T cell immunity in colorectal cancer rats. Cell Physiol Biochem 42:2330–2341. https://doi.org/10.1159/000480005

    Article  CAS  PubMed  Google Scholar 

  27. Zwielehner J, Lassl C, Hippe B, Pointner A, Switzeny OJ, Remely M, Kitzweger E, Ruckser R, Haslberger AG (2011) Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting. PLoS ONE 6(12):e28654. https://doi.org/10.1371/journal.pone.0028654

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM (2017) Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol 14:356–365. https://doi.org/10.1038/nrgastro.2017.20

    Article  CAS  PubMed  Google Scholar 

  29. Fijlstra M, Ferdous M, Koning AM, Rings EH, Harmsen HJ, Tissing WJ (2015) Substantial decreases in the number and diversity of microbiota during chemotherapy-induced gastrointestinal mucositis in a rat model. Support Care Cancer 23:1513–1522. https://doi.org/10.1007/s00520-014-2487-6

    Article  PubMed  Google Scholar 

  30. Wexler HM (2007) Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 20:593–621. https://doi.org/10.1128/CMR.00008-07

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Saint-Cyr MJ, Perrin-Guyomard A, Houee P, Rolland JG, Laurentie M (2013) Evaluation of an oral subchronic exposure of deoxynivalenol on the composition of human gut microbiota in a model of human microbiota-associated rats. PLoS ONE 8(11):e80578. https://doi.org/10.1371/journal.pone.0080578

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Precup G, Vodnar DC (2019) Gut Prevotella as a possible biomarker of diet and its eubiotic versus dysbiotic roles: a comprehensive literature review. Br J Nutr 122:131–140. https://doi.org/10.1017/S0007114519000680

    Article  CAS  PubMed  Google Scholar 

  33. Kovatcheva-Datchary P, Nilsson A, Akrami R, Lee YS, De Vadder F, Arora T, Hallen A, Martens E, Bjorck I, Backhed F (2015) Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of Prevotella. Cell Metab 22:971–982. https://doi.org/10.1016/j.cmet.2015.10.001

    Article  CAS  PubMed  Google Scholar 

  34. Koren O, Knights D, Gonzalez A, Waldron L, Segata N, Knight R, Huttenhower C, Ley RE (2013) A guide to enterotypes across the human body: meta-analysis of microbial community structures in human microbiome datasets. PLOS Comput Biol 9:e1002863. https://doi.org/10.1371/journal.pcbi.1002863

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Veloo ACM, Baas WH, Haan FJ, Coco J, Rossen JW (2019) Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect 25:1156 e1159–1156 e1113. https://doi.org/10.1016/j.cmi.2019.02.017

  36. Forsgard RA, Marrachelli VG, Korpela K, Frias R, Collado MC, Korpela R, Monleon D, Spillmann T, Osterlund P (2017) Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats. Cancer Chemother Pharmacol 80:317–332. https://doi.org/10.1007/s00280-017-3364-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank the central laboratory of School of Life Science, Lanzhou University, for providing various instruments and equipment.

Funding

This work was supported by Fundamental Research Funds for the Central Universities grant (grant numbers: lzujbky-2017-br01), National Natural Science Foundation grant (grant numbers: 31870082), and Lanzhou science and technology plan project (grant numbers: 2019-4-40).

Author information

Author notes

  1. Wenzhen Yuan and Xingpeng Xiao contributed equally to this work.

Authors and Affiliations

  1. The First Hospital of Lanzhou University, Donggangxilu #1, Lanzhou, 730000, Gansu, Republic of China

    Wenzhen Yuan

  2. Ministry of Education Key Laboratory of Cell Activities and Stress Adaptations, School of Life Science, Lanzhou University, Tianshuinanlu #222, Lanzhou, 730000, Gansu, Republic of China

    Xingpeng Xiao, Xuan Yu, Fuquan Xie, Pengya Feng, Kamran Malik, Ze Ye & Xiangkai Li

  3. Key Laboratory for Resources Utilization Technology of Unconventional Water of Gansu Province, Gansu Academy of Membrane Science and Technology, Lanzhou, 730020, Gansu, Republic of China

    Peng Zhang

  4. The First Clinical Medical College of Lanzhou University, Tianshuinanlu #222, Lanzhou, 730000, Gansu, Republic of China

    Jingyuan Wu

Authors
  1. Wenzhen Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xingpeng Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xuan Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fuquan Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pengya Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kamran Malik
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jingyuan Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ze Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Peng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xiangkai Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization, Wenzhen Yuan and Xingpeng Xiao; Methodology, Xingpeng Xiao; Software, Fuquan Xie, Jingyuan Wu; Investigation, Xingpeng Xiao, Xuan Yu, Pengya Feng, and Ze Ye; Resources, Peng Zhang, Wenzhen Yuan, and Xiangkai Li; Writing—original draft preparation, Xuan Yu; Writing—review and editing, Kamran Malik; Project administration, Xiangkai Li. All authors have read and agreed to the published version of the manuscript.

Corresponding authors

Correspondence to Xuan Yu or Xiangkai Li.

Ethics declarations

Ethics Approval

All the animal experiments were performed in accordance with the approval of the Committee on the Ethics of Animal Experiments of School of Life Sciences of Lanzhou University, China (201912021).

Consent to Participate

In the research that involves human subjects, all subjects gave their informed consent for inclusion before they participated in the study.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 12 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yuan, W., Xiao, X., Yu, X. et al. Probiotic Therapy (BIO-THREE) Mitigates Intestinal Microbial Imbalance and Intestinal Damage Caused by Oxaliplatin. Probiotics & Antimicro. Prot. 14, 60–71 (2022). https://doi.org/10.1007/s12602-021-09795-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12602-021-09795-3

Keywords

Search

Navigation